German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.
The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine candidate, SparVax.
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Several biopharma players--including Emergent Biosolutions, GlaxoSmithKline and Novartis--landed on the winning end of contracts from the U.S. Department of Health and Human Services to develop and churn out treatments against bioterror and pandemic threats. To fund the first phase of the effort, the HHS has committed $400 million.
Emergent BioSolutions ($EBS) has suffered a setback in its campaign to expand into cancer drug development. Abbott Labs ($ABT) has decided to dump a partnership with Emergent on the development of
Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the
In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study